AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15036672 — intervention group
Group type: COMPARATOR
Intervention: Standard side-notch needle
Number of subjects: 86
Study 15036672 — intervention group
Group type: EXPERIMENTAL
Intervention: End-cut needle (BioPince) with 33mm stroke length
Number of subjects: 86
Study 15036672 — intervention group
Group type: EXPERIMENTAL
Intervention: End-cut needle (BioPince) with stroke lengths of 13mm and 23mm
Number of subjects: 86
Study 11702866 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch and nimodipine for an average of 9 days
Number of subjects: 41
Study 11702866 — intervention group
Group type: COMPARATOR
Intervention: No postoperative medical treatment
Number of subjects: 41
Study 9393050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-relief mattresses
Number of subjects: 0
Study 7948449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion
Number of subjects: 20
Study 3371138 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (150 mg twice daily)
Number of subjects: 40
Study 3371138 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (25 mg four times daily)
Number of subjects: 40
Study 29277125 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% subsidy
Number of subjects: 23023
Study 29277125 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% subsidy
Number of subjects: 23023
Study 29277125 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% subsidy
Number of subjects: 23023
Study 29277125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid 50% subsidy
Number of subjects: 23023
Study 29277125 — intervention group
Group type: COMPARATOR
Intervention: All groups (100%, 80%, 50%, hybrid)
Number of subjects: 23023
Study 26889992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealer device
Number of subjects: 100
Study 26889992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bipolar sealer device)
Number of subjects: 100
Study 26386801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) designed to achieve and maintain weight loss through caloric reduction and increased physical activity
Number of subjects: 5067
Study 26386801 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education usual care group
Number of subjects: 5067
Study 26386801 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during the first year of the intervention
Number of subjects: 5067
Study 26386801 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in physical fitness during the first year of the intervention
Number of subjects: 5067
Study 24076594 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 μg 1,25-dihydroxy cholecalciferol per capsule, 2 capsules per day)
Number of subjects: 70
Study 24076594 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 70
Study 20107916 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person interpretation
Number of subjects: 241
Study 20107916 — intervention group
Group type: COMPARATOR
Intervention: Video interpretation
Number of subjects: 241
Study 20107916 — intervention group
Group type: COMPARATOR
Intervention: Telephonic interpretation
Number of subjects: 241
Study 20107916 — intervention group
Group type: COMPARATOR
Intervention: All methods (in-person, video, telephonic)
Number of subjects: 241
Study 19113053 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed wound drainage with suction (26 patients)
Number of subjects: 50
Study 19113053 — intervention group
Group type: COMPARATOR
Intervention: Closed wound drainage without suction (24 patients)
Number of subjects: 50
Study 16009883 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 30 microg IM once weekly
Number of subjects: 795
Study 16009883 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a 60 microg IM once weekly
Number of subjects: 795
Study 16009883 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb+ patients
Number of subjects: 795
Study 12616704 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 44 additional weeks after initial therapy
Number of subjects: 504
Study 12616704 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 68 additional weeks after initial therapy
Number of subjects: 504
Study 12616704 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous once-weekly, and ribavirin, 400 mg b.i.d. for 20 additional weeks after initial therapy
Number of subjects: 504
Study 12616704 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 504
Study 10357339 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) added to 40 mL of 0.5% lidocaine
Number of subjects: 40
Study 10357339 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline added to 40 mL of 0.5% lidocaine (Control)
Number of subjects: 40
Study 8603942 — intervention group
Group type: EXPERIMENTAL
Intervention: pentavalent Corynebacterium diphtheriae C7 (beta197) CRM197 protein‐conjugated pneumococcal vaccine (CV)
Number of subjects: 46
Study 8603942 — intervention group
Group type: COMPARATOR
Intervention: licensed (23‐valent, 25 microgram/serotype) pneumococcal polysaccharide vaccine (PV)
Number of subjects: 46
Study 8603942 — intervention group
Group type: EXPERIMENTAL
Intervention: reimmunization with PV after initial CV
Number of subjects: 46
Study 1758717 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) catheters
Number of subjects: 300
Study 1758717 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene (PE) catheters
Number of subjects: 300
Study 7199854 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of cocaine HCl solution administered intranasally
Number of subjects: 16
Study 7199854 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo administered intranasally
Number of subjects: 16
Study 31752964 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated electronic health record (EHR) and community health worker (CHW) intervention including group education sessions on diabetes prevention, weight loss, and nutrition.
Number of subjects: 480
Study 31752964 — intervention group
Group type: COMPARATOR
Intervention: Matched control group receiving standard care without the integrated EHR and CHW intervention.
Number of subjects: 480
Study 29371080 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoscopy Simulation (OS)
Number of subjects: 29
Study 29371080 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Module (WM)
Number of subjects: 29
Study 29371080 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Instruction (SI)
Number of subjects: 29
Study 26685106 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D TSE MRI with 6-fold acceleration (10-minute protocol)
Number of subjects: 30
Study 26685106 — intervention group
Group type: COMPARATOR
Intervention: 2D TSE MRI (20-minute protocol)
Number of subjects: 30
Study 25451907 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone delivered translation of the DPP weight loss program, delivered by trained primary care staff over 2 years.
Number of subjects: 0
Study 25451907 — intervention group
Group type: COMPARATOR
Intervention: Individual calls (control group).
Number of subjects: 0
Study 22065199 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy
Number of subjects: 215
Study 22065199 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT subgroup analysis
Number of subjects: 215
Study 22065199 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 215
Study 22065199 — intervention group
Group type: COMPARATOR
Intervention: Complete resection
Number of subjects: 215
Study 22065199 — intervention group
Group type: COMPARATOR
Intervention: Postprogression second surgery
Number of subjects: 215
Study 19233759 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG surgery
Number of subjects: 66
Study 16501591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 4.0 mg/m2/day x 5 days
Number of subjects: 49
Study 16501591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 7 mg/m2/day
Number of subjects: 49
Study 16501591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 9.5 mg/m2/day
Number of subjects: 49
Study 16501591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 9 mg/m2/day x 5 days
Number of subjects: 49
Study 16501591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 4-9.0 mg/m2/day
Number of subjects: 49
Study 16501591 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan at 9 mg/m2/day
Number of subjects: 49
Study 12573207 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch/hazel-SLIT + Grass-SIT
Number of subjects: 36
Study 12573207 — intervention group
Group type: COMPARATOR
Intervention: Grass-SIT
Number of subjects: 36
Study 11004067 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) clamped
Number of subjects: 10
Study 11004067 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic laryngeal mask airway (LMA)
Number of subjects: 10
Study 11004067 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) unclamped
Number of subjects: 10
Study 11004067 — intervention group
Group type: COMPARATOR
Intervention: Control (no airway device)
Number of subjects: 10
Study 8842660 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 90
Study 8842660 — intervention group
Group type: COMPARATOR
Intervention: suxamethonium 1 mg kg‐1
Number of subjects: 90
Study 1588355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowasa I (placebo-controlled)
Number of subjects: 0
Study 1588355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6386486 — intervention group
Group type: EXPERIMENTAL
Intervention: penbutolol 40 mg single dose
Number of subjects: 30
Study 6386486 — intervention group
Group type: EXPERIMENTAL
Intervention: combined therapy (penbutolol + molsidomine 2 mg single dose)
Number of subjects: 30
Study 6386486 — intervention group
Group type: COMPARATOR
Intervention: beta blocker alone
Number of subjects: 30
Study 31648204 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Training (MMT)
Number of subjects: 21
Study 31648204 — intervention group
Group type: COMPARATOR
Intervention: Single-Modal Training (SMT)
Number of subjects: 21
Study 29494424 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct delivery of HIV self-tests from a peer educator
Number of subjects: 965
Study 29494424 — intervention group
Group type: EXPERIMENTAL
Intervention: Free facility-based delivery of HIV self-tests in exchange for coupons
Number of subjects: 965
Study 29494424 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care HIV testing
Number of subjects: 965
Study 26891621 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental individual‐difference, relationship‐based/floortime (DIR/FT) group (n = 20)
Number of subjects: 40
Study 26891621 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational (wait-list) group (n = 20)
Number of subjects: 40
Study 24687927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant FOLFOX alone or combined with cetuximab
Number of subjects: 2478
Study 24687927 — intervention group
Group type: COMPARATOR
Intervention: Wild-type KRAS/BRAF tumors
Number of subjects: 2478
Study 22704583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years
Number of subjects: 3323
Study 22704583 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years (in women age 50 years or older)
Number of subjects: 3323
Study 22704583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3323
Study 20715086 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic-assisted adenoidectomy
Number of subjects: 38
Study 20715086 — intervention group
Group type: COMPARATOR
Intervention: Curettage adenoidectomy
Number of subjects: 38
Study 17005329 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management
Number of subjects: 393
Study 17005329 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 393
Study 17319251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus tramadol 100 mg (Group 2)
Number of subjects: 60
Study 17319251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus clonidine 1 microg/kg (Group 3)
Number of subjects: 60
Study 17319251 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (Group 1)
Number of subjects: 60
Study 11978744 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife
Number of subjects: 826
Study 11978744 — intervention group
Group type: COMPARATOR
Intervention: SHO (junior paediatrician)
Number of subjects: 826
Study 11978744 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of healthcare issues
Number of subjects: 826
Study 11978744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of care
Number of subjects: 826
Study 11978744 — intervention group
Group type: EXPERIMENTAL
Intervention: History of miscarriage
Number of subjects: 826
Study 9916961 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nitroglycerin
Number of subjects: 31
Study 9916961 — intervention group
Group type: COMPARATOR
Intervention: IV magnesium sulfate
Number of subjects: 31
Study 7754537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) by electron beam
Number of subjects: 54
Study 7754537 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-IORT)
Number of subjects: 54
Study 2076398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg slow-release nifedipine
Number of subjects: 9
Study 2076398 — intervention group
Group type: COMPARATOR
Intervention: 5 mg isosorbide dinitrate
Number of subjects: 9
Study 7000243 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 23
Study 7000243 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (160 mg/day)
Number of subjects: 23
Study 7000243 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release oxprenolol (160 mg/day)
Number of subjects: 23
Study 7000243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31690616 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental PEEP titration (randomized to -6, -3, +3, and +6 cm H2O)
Number of subjects: 14
Study 31690616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure positive
Number of subjects: 14
Study 31690616 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-operator variability assessment
Number of subjects: 14
Study 30796496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 Gy (arm-A)
Number of subjects: 184
Study 30796496 — intervention group
Group type: COMPARATOR
Intervention: Postoperative whole-breast radiation therapy (WBRT) up to 56 Gy in 2 Gy fractions (arm-B)
Number of subjects: 184
Study 27450571 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy-based text messaging (daily messages 6 days per week for 12 weeks)
Number of subjects: 190
Study 26225993 — intervention group
Group type: EXPERIMENTAL
Intervention: MVM + G
Number of subjects: 40
Study 26225993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23672349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 219
Study 20816041 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 54
Study 20816041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19683392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal glycine (ITG) treatment for 4 weeks
Number of subjects: 19
Study 19683392 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 16893698 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 106
Study 16893698 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 106
Study 12542733 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG-N
Number of subjects: 63
Study 12542733 — intervention group
Group type: COMPARATOR
Intervention: Sandoglobulin
Number of subjects: 63
Study 10701032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 100 micrograms/kg at induction (Group 1)
Number of subjects: 120
Study 10701032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 100 micrograms/kg at the end of surgery (Group 2)
Number of subjects: 120
Study 9432300 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic drugs
Number of subjects: 3
Study 9432300 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration of neuro‐ and psychasthenic forms of cerebral artery atherosclerosis
Number of subjects: 3
Study 9432300 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 3
Study 9432300 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 3
Study 1589702 — intervention group
Group type: EXPERIMENTAL
Intervention: Al(OH)3 and Mg(OH)2 (preparation A)
Number of subjects: 18
Study 1589702 — intervention group
Group type: EXPERIMENTAL
Intervention: AlPO4 (preparation B)
Number of subjects: 18
Study 1589702 — intervention group
Group type: COMPARATOR
Intervention: Antacid or placebo medication
Number of subjects: 18
Study 3910604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days)
Number of subjects: 80
Study 3910604 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (dosage not specified)
Number of subjects: 80
Study 29752869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of non-HLA matched, ABO matched, unrelated allogeneic umbilical cord blood (UCB)
Number of subjects: 10
Study 26335028 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% mTSC, 80 Hz, 400 μs
Number of subjects: 13
Study 26335028 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% mTSC, 80 Hz, 400 μs
Number of subjects: 13
Study 26335028 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% mTSC, 20 Hz, 400 μs
Number of subjects: 13
Study 26335028 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% mTSC, 20 Hz, 400 μs
Number of subjects: 13
Study 26335028 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% mTSC, 80 Hz, 150 μs
Number of subjects: 13
Study 26335028 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% mTSC, 80 Hz, 150 μs
Number of subjects: 13
Study 26335028 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 13
Study 25293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Echium oil (7.5 ml b.i.d., 235 mg/ml α-linolenic acid + 95 mg/ml stearidonic acid + 79 mg/ml γ-linolenic acid)
Number of subjects: 91
Study 25293388 — intervention group
Group type: COMPARATOR
Intervention: n-3 FA deficient sunflower oil high oleic (7.5 ml b.i.d.)
Number of subjects: 91
Study 25293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Echium oil
Number of subjects: 91
Study 25293388 — intervention group
Group type: COMPARATOR
Intervention: n-3 FA deficient sunflower oil high oleic
Number of subjects: 91
Study 22913889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus colesevelam
Number of subjects: 0
Study 22913889 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 0
Study 19809806 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplanar osteotomy with a short spacer plate (group 1)
Number of subjects: 24
Study 19809806 — intervention group
Group type: EXPERIMENTAL
Intervention: Biplanar osteotomy with a long and rigid plate fixator (group 2)
Number of subjects: 24
Study 19809806 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplanar osteotomy with a short spacer plate (group 1)
Number of subjects: 24
Study 19809806 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniplanar osteotomy with a long and rigid plate fixator (group 2)
Number of subjects: 24
Study 18005842 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus SEP with Transbond XT adhesive
Number of subjects: 36
Study 18005842 — intervention group
Group type: COMPARATOR
Intervention: Ideal 1 SEP with Ideal 1 adhesive
Number of subjects: 36
Study 16052193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 189
Study 16052193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 12382384 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% nitrous oxide
Number of subjects: 30
Study 12382384 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone (control group)
Number of subjects: 30
Study 12904156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0
Study 12904156 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antimalaria drugs
Number of subjects: 0
Study 9504513 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management (prophylactic oxytocic within 2 min of baby's birth, immediate cutting and clamping of the cord, delivery of placenta by controlled cord traction or maternal effort)
Number of subjects: 1512
Study 9504513 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (no prophylactic oxytocic, no cord clamping until pulsation ceased, delivery of placenta by maternal effort)
Number of subjects: 1512
Study 9504513 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 1512
Study 9504513 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1512
Study 7846197 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 148
Study 7846197 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters who returned to previous smoking level
Number of subjects: 148
Study 7846197 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitters who remained abstinent or smoked occasionally
Number of subjects: 148
Study 7846197 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking group (control)
Number of subjects: 148
Study 30317339 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 76
Study 30317339 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 76